Search Results

You are looking at 1 - 3 of 3 items for

  • Author: Maria Kowalska x
Clear All Modify Search
Malgorzata Fuksiewicz Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Search for other papers by Malgorzata Fuksiewicz in
Google Scholar
PubMed
Close
,
Maria Kowalska Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Search for other papers by Maria Kowalska in
Google Scholar
PubMed
Close
,
Agnieszka Kolasinska-Cwikla Department of Oncology and Radiotherapy, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Search for other papers by Agnieszka Kolasinska-Cwikla in
Google Scholar
PubMed
Close
, and
Beata Kotowicz Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Search for other papers by Beata Kotowicz in
Google Scholar
PubMed
Close

The aim of this study was to assess the usefulness of neuron-specific enolase (NSE) concentrations as a prognostic factor in patients with neuroendocrine neoplasms and to determine the relationship between NSE and clinicopathological features. Serum NSE levels were measured in 179 NEN patients before treatment. It was found that NSE levels in patients with a primary pancreatic location were higher compared to patients with a small intestine lesion (P = 0.015). NSE levels were significantly higher in patients with primary pancreatic location with histological grade G2 compared with the group with low-grade G1 (P = 0.047). Patients with initial liver involvement showed significantly higher NSE levels compared to patients with tumour location in the pancreas (P = 0.009). Statistical analysis confirmed that higher NSE levels were associated with disease progression (P = 0.001) in both the overall study group and in patients with tumours in the pancreas and small intestine. During treatment monitoring, an increase in median NSE concentrations was observed in patients with persistent progression with subsequent blood draws, and a decrease in NSE concentrations was observed in patients with disease stabilisation. We showed that NSE concentrations have prognostic value for progression-free survival in addition to primary liver involvement. In conclusion, the most important results of the study include the demonstration of an association between NSE concentrations and clinical status, which confirms its usefulness in patient monitoring and as a potential predictive indicator for progression-free survival in patients with NENs.

Open access
Agnieszka Adamska Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, Białystok, Poland

Search for other papers by Agnieszka Adamska in
Google Scholar
PubMed
Close
,
Aleksandra Maria Polak Department of Internal Medicine and Metabolic Diseases, Medical University of Białystok, Białystok, Poland

Search for other papers by Aleksandra Maria Polak in
Google Scholar
PubMed
Close
,
Anna Krentowska Department of Internal Medicine and Metabolic Diseases, Medical University of Białystok, Białystok, Poland

Search for other papers by Anna Krentowska in
Google Scholar
PubMed
Close
,
Agnieszka Łebkowska Department of Internal Medicine and Metabolic Diseases, Medical University of Białystok, Białystok, Poland

Search for other papers by Agnieszka Łebkowska in
Google Scholar
PubMed
Close
,
Justyna Hryniewicka Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, Białystok, Poland

Search for other papers by Justyna Hryniewicka in
Google Scholar
PubMed
Close
,
Monika Leśniewska Department of Reproduction and Gynecological Endocrinology, Medical University of Białystok, Białystok, Poland

Search for other papers by Monika Leśniewska in
Google Scholar
PubMed
Close
, and
Irina Kowalska Department of Internal Medicine and Metabolic Diseases, Medical University of Białystok, Białystok, Poland

Search for other papers by Irina Kowalska in
Google Scholar
PubMed
Close

Objective

PCOS women are characterized by insulin resistance and have higher tendency to the development of hepatic steatosis. Fetuin-B has been introduced as a hepatokine/adipokine, which is increased in hepatic steatosis and may be connected with glucose metabolism disturbances. The aim of the study was to evaluate the relationships between serum fetuin-B concentration and indices of insulin resistance, insulin secretion and markers of liver steatosis in PCOS women in comparison to the control group.

Patients and methods

The study group included 108 women – 57 women with PCOS and 51 women matched for age and BMI as a control group. Serum concentration of fetuin-B was estimated. Homeostasis model assessment of insulin resistance (HOMA-IR) and homeostasis model assessment β cell function (HOMA-β) were calculated. Fatty liver index (FLI), lipid accumulation product (LAP) and visceral adiposity index (VAI) were used as markers of liver steatosis.

Results

We found higher serum concentration of fetuin-B and FLI in PCOS women in comparison to the control group (all P < 0.05). We observed a positive relationship between serum fetuin-B concentration and HOMA-β (r = 0.43, P = 0.01), HOMA-IR (r = 0.31, P = 0.01), FLI (r = 0.29, P = 0.02), VAI (r = 0.29, P = 0.02) and LAP (r = 0.32, P = 0.01) in PCOS women. We also noticed a relationship between HOMA-IR and FLI (r = 0.42, P = 0.01), VAI (r = 0.38, P = 0.004) and LAP (r = 0.41, P = 0.001) in this group. Multiple regression analysis revealed that HOMA-β (β = 0.39, P = 0.002) and LAP (β = 0.27, P = 0.02) were independently connected with serum fetuin-B levels in women with PCOS.

Conclusions

Serum fetuin-B levels are higher in women with PCOS and are independently connected with HOMA-β and hepatic steatosis.

Open access
Małgorzata Fuksiewicz Department of Pathology and Laboratory Diagnostics, Laboratory of Tumor Markers, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

Search for other papers by Małgorzata Fuksiewicz in
Google Scholar
PubMed
Close
,
Maria Kowalska Department of Pathology and Laboratory Diagnostics, Laboratory of Tumor Markers, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

Search for other papers by Maria Kowalska in
Google Scholar
PubMed
Close
,
Agnieszka Kolasińska-Ćwikła Department of Oncology and Radiotherapy, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

Search for other papers by Agnieszka Kolasińska-Ćwikła in
Google Scholar
PubMed
Close
,
Jarosław B Ćwikła The Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, Poland

Search for other papers by Jarosław B Ćwikła in
Google Scholar
PubMed
Close
,
Łukasz Sawicki Department of Clinical Surgery, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

Search for other papers by Łukasz Sawicki in
Google Scholar
PubMed
Close
,
Katarzyna Roszkowska-Purska Department of Pathology, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

Search for other papers by Katarzyna Roszkowska-Purska in
Google Scholar
PubMed
Close
,
Joanna Drygiel Department of Nutrition, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

Search for other papers by Joanna Drygiel in
Google Scholar
PubMed
Close
, and
Beata Kotowicz Department of Pathology and Laboratory Diagnostics, Laboratory of Tumor Markers, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

Search for other papers by Beata Kotowicz in
Google Scholar
PubMed
Close

The aim of this study was to evaluate the clinical usefulness of the chromogranin A (CgA) determination in patients with neuroendocrine neoplasms (NENs) of the digestive system and to analyse the association between concentration of the marker and progression-free survival (PFS) and overall survival (OS). Serum concentrations of CgA were determined before the treatment in 131 patients with NENs, including patients with tumours located in the pancreas, the small intestine, caecum, appendix and in the colon. No significant associations were identified in CgA concentrations between the control group and patients with NENs in appendix and colon. In patients with NENs of the pancreas and NENs of the small intestine and caecum, increased CgA levels were associated with lymph node involvement, distant metastases and a baseline liver involvement. Analyses revealed significantly higher CgA concentrations in patients with active disease compared to those without symptoms of NEN. In patients with NENs of the pancreas, CgA concentration was correlated with tumour grade and Ki67. Significantly higher CgA levels were also found in patients who died compared to those who lived. Analyses of PFS and OS revealed that CgA concentration was not a prognostic factor in patients with NENs of the pancreas. In patients with NENs of the small intestine and caecum, increased CgA concentrations are independent, poor prognostic factors for both PFS and OS. In conclusion, in patients with NENs in pancreas, CgA levels are associated with disease progression, while in patients with NENs in small intestine and caecum, its concentration is a predictive indicator for PFS and OS.

Open access